Arvinas heads into the back half of August with short sellers quietly retreating, options positioning turning more constructive, and the analyst community split between trimmed targets and stubborn buy ratings — all against a stock that has clawed back 13% in a month but still trades below $10.
The positioning story is the clearest positive this week. Short interest has fallen steadily, dropping roughly 10% over the past month to 6.1% of the free float — still a meaningful level, but the direction of travel has shifted. The borrow market tells the same story from the other side: availability is extraordinarily loose, with roughly 45.8 million shares available for lending relative to the ~3.9 million currently borrowed. That ratio — an availability figure running well into the thousands of percent — signals there is no supply-side pressure on shorts whatsoever. Cost to borrow reflects the same relaxed conditions, running at just 0.64%, even after ticking up 48% on the week from very low levels. The ORTEX short score of 45 sits comfortably in neutral territory, having drifted lower from around 46 two weeks ago. Positioning looks less hostile than it has in months.
Options traders have become notably more bullish than usual. The put/call ratio has dropped to 0.36, almost two standard deviations below its 20-day average of 0.42 — and that move is recent and sharp, with the ratio declining nearly every session since August 14. The 52-week low on this measure is 0.12, so there is room to run further, but the direction shift is clear: calls are increasingly outweighing puts, suggesting market participants are positioning for more upside rather than hedging against a fall. That is a meaningful reversal from the more cautious tone that prevailed through most of July and early August.
The Street reaction to the most recent earnings print — Q2 results on August 4 — tells a complicated story. The stock moved up roughly 4% the day after, then extended to nearly 12% over five sessions, which is the positive backdrop behind the current price level. But analysts used the event to recalibrate. Evercore ISI cut its target from $19 to $14, maintaining Outperform. Citi trimmed from $24 to $21, keeping Buy. Wells Fargo went further — downgrading to Equal-Weight and cutting to $11 — while BTIG stood firm at Buy with an $18 target. The net effect: the consensus mean target is $13.93, implying roughly 49% upside from the current $9.37. Bulls are anchored to the protein degradation platform and the commercial progress of VEPPANU; bears are focused on pipeline execution risk, competition from Biogen's BIIB122 in the LRRK2 pathway, and the reality that any expansion into earlier treatment lines now depends on partner Rigel's commercial strategy rather than Arvinas itself.
Institutional flow adds a mildly encouraging footnote. BlackRock added 811,539 shares in its most recent filing, lifting its stake to 11.6% of shares outstanding. Armistice Capital built a fresh position of 2.8 million shares. Two Sigma added 741,333 shares. These are reported through July, so they predate the August earnings print, but the cluster of additions from funds of different styles — passive, quant, and multi-strategy — suggests the stock attracted interest at lower price levels. Insider activity, by contrast, has been entirely one-directional: the CFO, CEO, CSO, and CMO all sold modest amounts in May and June, though at low prices and low significance scores, consistent with routine plan sales rather than a deliberate reduction in exposure.
The next scheduled earnings event is November 4. Between now and then, clinical updates on ARV-102 — where biomarker data is generating attention — and any news on VEPPANU's commercial trajectory with Rigel will be the data points most likely to drive the next material move in either direction.
See the live data behind this article on ORTEX.
Open ARVN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
